Vapes were invented to give smokers a way to get nicotine without inhaling the thousands of toxic byproducts created by burning tobacco. The modern e-cigarette traces back to a Chinese pharmacist named Hon Lik, who patented his ultrasonic vaporizing device in 2003 after watching his father die of lung cancer. But the idea of an electronic nicotine delivery system had been percolating in tobacco industry labs for over a decade before that, driven by the same basic premise: combustion is what makes cigarettes deadly, so remove the combustion. The story of how that harm-reduction idea became a global consumer product, a cessation tool, and a public-health controversy all at once is more tangled than most people realize.
A Pharmacist’s Grief and a Tobacco Company’s Strategy
Hon Lik was a heavy smoker and a pharmacist in Shenyang, China. When his father, also a lifelong smoker, died of lung cancer, Hon Lik began experimenting with a device that would heat a nicotine-containing liquid into an inhalable aerosol. He filed his patent in 2003, and by 2004 his employer, Golden Dragon Holdings (later Ruyan), was selling the product in China. Within a few years it had reached European and American markets. This is the origin story most people know.
What’s less widely known is that Philip Morris had been pursuing essentially the same concept since 1990. Internal company documents show that PM began developing a nicotine aerosol device specifically to address health concerns and the declining social acceptability of smoking, which were pushing smokers toward nicotine replacement products like patches and gum. By 1993, PM had created what it called the “Ideal Smoke” program, with two explicit goals: build a satisfying product that addressed consumers’ health fears, and design something the medical community might endorse as less harmful than cigarettes without it falling under FDA drug regulation.1PubMed Central. Philip Morris research on precursors to the modern e-cigarette since 1990 That second goal reveals a lot about the corporate calculus at play: harm reduction was the stated motivation, but navigating regulation was the strategic priority.
Neither PM’s early prototypes nor Hon Lik’s first-generation “cigalike” devices were particularly good at delivering nicotine. They looked like cigarettes, they produced a modest puff of vapor, and they gave users a fraction of the nicotine hit that a real cigarette delivered. But they proved the concept. You could aerosolize a nicotine solution, inhale it, and skip the tar, carbon monoxide, and carcinogens that come from setting plant matter on fire.
What Vape Aerosol Actually Contains
The core claim behind e-cigarettes has always been that their aerosol is dramatically cleaner than cigarette smoke. The evidence on this point is surprisingly lopsided. Cigarette smoke is a staggeringly complex mixture; when researchers have compared the two head-to-head, the difference in harmful compounds is not subtle.
One quantitative analysis examined 150 potential toxicants in e-cigarette aerosol and found that 104 were not detected at all, while another 21 showed up only as laboratory background contamination. Of the compounds the e-cigarette actually generated, most were major e-liquid ingredients (nicotine, propylene glycol, glycerol) or their thermal breakdown products. Cigarette smoke, by contrast, contained roughly 100 detectable toxicants from the same measurement panel. Depending on which regulatory list of harmful compounds was used, e-cigarette emissions ran between 82% and more than 99% lower per puff than cigarette smoke.2PubMed. Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke
A separate study measuring harmful and potentially harmful constituents found that conventional cigarette smoke delivered roughly 1,500 times more of these compounds than e-cigarette aerosol. The e-cigarette readings were so low they were comparable to the ambient room air used as a control.3PubMed. Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air That doesn’t mean e-cigarette aerosol is harmless, and the researchers were careful not to say so. But as a relative comparison, the gap between cigarette smoke and vape aerosol is enormous.
England’s public health agency leaned heavily on this kind of evidence when it began promoting e-cigarettes as a cessation aid, stating publicly that vaping is at least 95% safer than smoking.4BMJ. Public Health England insists e-cigarettes are 95% safer than smoking That figure has been debated and criticized as overconfident, but the directional claim that e-cigarettes expose users to far fewer toxicants than combustible cigarettes is well supported by the chemistry.
How Nicotine Delivery Evolved Across Device Generations
For a harm reduction product to work, it has to be satisfying enough that smokers actually switch. Early e-cigarettes failed at this for a basic pharmacological reason: they delivered nicotine too slowly. Smoking a single conventional cigarette raises blood nicotine levels to around 15 ng/mL or higher within about five minutes. First-generation cigalikes couldn’t come close. One study found that after ten puffs, a first-generation device raised plasma nicotine only from about 2.8 to 4.9 ng/mL, roughly a quarter of what a cigarette would achieve in the same window. A newer, larger device with a refillable tank did better, reaching about 6.6 ng/mL, but still fell well short.5Scientific Reports. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices
This speed gap matters because the reinforcing properties of nicotine depend heavily on how quickly it reaches the brain. A slow trickle of nicotine is far less satisfying than a rapid spike, which is why nicotine gum and patches help with withdrawal but rarely replicate the subjective experience of smoking. Even newer tank-style devices, while more efficient than cigalikes, still lagged behind cigarettes in delivery speed.6PubMed Central. Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers)
The introduction of pod-based systems changed the equation. When researchers measured nicotine delivery from a popular pod device among experienced users who took 30 puffs in 10 minutes, the average nicotine boost was 28.6 ng/mL in about 8.7 minutes. For comparison, earlier cigalike devices delivered only about 1.8 ng/mL and tank-style devices about 10.8 ng/mL under the same puffing protocol. The pod device’s nicotine delivery was comparable to smoking a cigarette.7JAMA Network Open. Nicotine Absorption Profile Among Regular Users of a Pod-Based Electronic Nicotine Delivery System The researchers noted that this capability could contribute both to the product’s addictiveness and to its ability to compete with cigarettes for market share, a duality that captures the entire e-cigarette dilemma in one sentence.
The Chemistry That Made Pods Work
The leap in nicotine delivery from early devices to pod systems wasn’t just about bigger batteries or better wicks. It was a chemistry change. Traditional e-liquids used freebase nicotine, the same form found in most cigarettes. Freebase nicotine at high concentrations is harsh on the throat, which limited how much nicotine manufacturers could pack into a liquid before it became unpleasant to inhale.
Pod manufacturers solved this by adding organic acids (most commonly benzoic acid) to the e-liquid, converting freebase nicotine into protonated nicotine salts. This lowered the pH, made the vapor smoother at high nicotine concentrations, and altered the pharmacokinetics in ways that improved craving relief.8PubMed. Toward Better Characterization of a Free-Base Nicotine Fraction in e-Liquids and Aerosols The result was a product that could deliver cigarette-level nicotine in a small, discreet form factor. This was a genuine engineering advance for harm reduction, making it easier for smokers to switch completely. It was also, inevitably, the innovation that made vaping explosively appealing to teenagers who had never smoked.
Quitting Smoking With E-Cigarettes
The clearest test of whether e-cigarettes fulfill their harm-reduction purpose is whether they actually help people quit smoking. The evidence here is strong and getting stronger. A Cochrane systematic review, the gold standard for synthesizing clinical trial data, found with high certainty that nicotine e-cigarettes increase quit rates compared to traditional nicotine replacement therapy like patches and gum. The effect translated to roughly four additional quitters per 100 people who tried.9PubMed Central. Electronic cigarettes for smoking cessation
Other meta-analyses have reached similar conclusions. One found that nicotine e-cigarettes were associated with roughly 77% higher odds of abstinence compared to conventional cessation therapies.10PubMed. Efficacy and Safety of E-Cigarette Use for Smoking Cessation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials A separate review that broke results down by follow-up period found the advantage of e-cigarettes over nicotine replacement was clearest at six months or longer, with more modest and less certain effects at shorter time windows.11PubMed Central. Electronic cigarettes versus nicotine-replacement therapy for smoking cessation: A systematic review and meta-analysis of randomized controlled trials
Part of the reason e-cigarettes outperform patches and gum may have nothing to do with nicotine pharmacology. Smoking is a deeply ritualized behavior, and the physical motions, the throat hit, the visible exhale, and the hand-to-mouth habit all contribute to its grip. In one survey of e-cigarette users, 84% said the sensation of the vapor was important in helping them quit smoking, and 91% believed the sensory experience contributed to their cessation success.12PubMed Central. Sensory experiences and cues among E-cigarette users This aligns with older research showing that many of the positive subjective effects of smoking come from airway sensory cues rather than nicotine itself; even denicotinized cigarettes produced comparable subjective satisfaction to regular ones in controlled experiments.13PubMed. Dissociating the nicotine and airway sensory effects of smoking E-cigarettes replicate these sensory cues in a way that a patch stuck to your arm never will.
The Dual-Use Problem
The harm-reduction logic only works if smokers actually switch. In practice, many people end up using both products simultaneously, a pattern researchers call dual use. This is concerning because dual users get exposed to toxicants from both cigarettes and e-cigarettes, and the evidence on whether dual use leads to eventual full switching is mixed.14PubMed Central. Dual Use of Combustible Cigarettes and E-cigarettes: a Narrative Review of Current Evidence
One study of cardiopulmonary symptoms found that dual users had greater overall toxicant exposure, consistent with earlier research showing that carcinogen and toxin levels in dual users were not substantially reduced compared to people who only smoked cigarettes.15PLoS ONE. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study In other words, cutting your cigarette consumption in half while vaping the rest of the time may not buy you much in terms of reduced harm. The benefit materializes when you quit combustible cigarettes entirely. For people who stall at dual use, the harm-reduction promise of vaping goes largely unfulfilled.
Risks That Remain
Dramatically less harmful than cigarettes is not the same as safe. E-cigarette aerosol still delivers substances into the lungs that would not be there otherwise, and the body responds to them. An animal study comparing e-cigarette vapor to cigarette smoke found that flavored nicotine vapor increased inflammatory markers and mucus production in the airways at levels comparable to, and in some cases higher than, cigarette smoke exposure over the same period. Airway hyperresponsiveness was also elevated in the flavored nicotine vapor group, similar to the cigarette smoke group.16PubMed. Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice This was a mouse study with high-dose exposures, so it shouldn’t be read as proof that vaping is as bad as smoking for human lungs, but it does show that the aerosol is not biologically inert.
On the cardiovascular side, a review of the evidence identified several concerning effects of e-cigarette use, including changes in blood lipids, shifts toward sympathetic nervous system dominance, damage to the lining of blood vessels, and activation of immune cells involved in plaque formation. Oxidative stress and inflammation appear to be the common thread linking many of these effects.17PubMed Central. Electronic Cigarette Use and the Risk of Cardiovascular Diseases The magnitude of these cardiovascular effects compared to cigarette smoking is still being worked out, but the point is that vaping is doing something to blood vessels, not nothing.
Flavorings add another layer of uncertainty. A systematic review of the pulmonary effects of e-liquid flavors found that cinnamon, strawberry, and menthol flavors showed the most pronounced harmful effects in lab studies, including increased inflammation and cell death. The chemical diacetyl (associated with buttery flavors) and cinnamaldehyde (the compound that gives cinnamon its taste) had enough evidence to support concerns about their safety when inhaled. For most other flavors, the safety data simply didn’t exist yet.18PubMed Central. Pulmonary effects of e-liquid flavors: a systematic review A chemical that’s safe to eat is not necessarily safe to breathe, and the flavoring industry developed these compounds for food, not for inhalation.
EVALI and the Importance of Distinguishing Products
In 2019, a wave of severe lung injuries swept across the United States, eventually labeled EVALI (e-cigarette, or vaping, product use-associated lung injury). The CDC documented 2,807 cases and at least 68 deaths by February 2020. The culprit turned out to be vitamin E acetate, an oily additive used as a thickening agent in illicit THC vape cartridges. EVALI cases were overwhelmingly associated with products containing THC purchased from informal sources, not with commercial nicotine e-cigarettes.19PubMed Central. The implications of Vitamin E acetate in E-cigarette, or vaping, product use-associated lung injury
The EVALI crisis is worth understanding because it had an outsized effect on public perception. The initial reporting lumped all vaping together, and surveys afterward showed a sharp increase in the percentage of Americans who believed nicotine e-cigarettes were as dangerous as or more dangerous than cigarettes. For people who study tobacco harm reduction, this was a setback: an epidemic caused by contaminated black-market THC products ended up discouraging smokers from using legal nicotine vapes to quit. The framing of harm reduction depends on the public being able to distinguish between different products and different risks, and EVALI showed how quickly that distinction can collapse.
Tobacco Harm Reduction as a Public Health Framework
The idea behind vaping did not emerge from nothing. It sits within a broader framework called tobacco harm reduction, which involves providing nicotine users who are unable or unwilling to stop using nicotine with less harmful ways to get it.20PubMed Central. Tobacco harm reduction: Past history, current controversies and a proposed approach for the future The philosophy mirrors harm-reduction approaches in other fields: needle exchange programs for people who inject drugs, for instance, do not require abstinence as a precondition for reducing risk. The logic is pragmatic. If millions of people are going to keep using nicotine regardless of what public health campaigns tell them, giving them a less lethal delivery method saves lives even if it doesn’t eliminate the behavior.
This framework is genuinely controversial. Critics argue that normalizing any nicotine product creates a gateway to cigarette smoking, particularly among young people. And the youth vaping numbers have given that concern real weight. Policies designed to curb adolescent vaping, such as flavor bans and high taxes, may also reduce adult smokers’ access to e-cigarettes for quit attempts, and scientists have warned that this trade-off deserves more careful consideration than it typically gets.21PubMed Central. Balancing Consideration of the Risks and Benefits of E-Cigarettes
How the US and UK Ended Up in Different Places
The regulatory divergence between the United States and the United Kingdom is striking. England’s public health system actively promotes e-cigarettes as a cessation tool and has incorporated them into its stop-smoking services. The US has taken a far more restrictive path. The FDA required e-cigarette manufacturers to submit premarket tobacco product applications, and by early 2023, over 25 million applications had received determinations. Of those, just 23 products received marketing authorization. Despite this, the number of unique devices and liquids people were actually using continued to grow, and fewer than 2% of frequent e-cigarette users were using FDA-authorized products.22PubMed Central. Decisions of the FDA on premarket tobacco product applications: Changes in the number of unique devices and liquids used by US adults who frequently use electronic nicotine delivery systems, 2020-2023
This gap between regulation and reality is its own kind of harm-reduction failure. When legal products are unavailable or restricted, users migrate to unregulated alternatives. And some early data suggests that taxing e-cigarettes heavily can nudge young people back toward combustible cigarettes. One study examining Minnesota’s e-cigarette tax, which rose from 35% to 95% between 2010 and 2013, found suggestive evidence that higher e-cigarette taxes increased youth cigarette consumption.23PubMed Central. Re-exploring the early relationship between teenage cigarette and e-cigarette use using price and tax changes The effect was modest and the statistical confidence was borderline, but the direction matters: if making vapes harder to get pushes even a small number of people toward cigarettes, the net health outcome is worse, not better.
The invention of e-cigarettes was, at its core, an attempt to separate nicotine from the combustion products that make smoking one of the leading causes of preventable death worldwide. Whether that invention ends up saving more lives than it costs depends less on the technology itself and more on how societies choose to regulate, promote, and restrict it. The science of relative risk is clearer than the politics will probably ever be.